Skip to main content

Table 1 Clinical data of the 30 untreated CLL patients tested for Ca2+ entry and dichotomized into CE+ (high constitutive Ca2+ entry [CE]) and CE- (low/normal CE levels) and of the whole CLL cohort (n = 74), dichotomized according to the level of STIM1 located in the plasma membrane (STIM1PM) in high and low

From: STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia

  CE-
(n = 14)
CE+
(n = 16)
Statistics High STIM1PM
(n = 28)
Low STIM1PM
(n = 44)
Statistics
Age diagnosis (years), mean ± SEM 63 ± 3 62 ± 2 NS 63 ± 2 64 ± 2 NS
Age analysis (years) 69 ± 4 67 ± 2 NS 70 ± 2 70 ± 2 NS
Sex F:M 4:10 8:8 NS 14:14 16:32 NS
Binet A/B/C 12/2/0 2/12/2 0.0002 13/10/5 31/10/3 NS
Cytogenetic risks, No (%)    NS    NS
 Low (isolated d13q) 6/12 (50%) 8/16 (50%)   13/26 (50%) 21/37 (56.8%)  
 Intermediate (tri12, normal karyotype) 6/12 (50%) 5/16 (31%)   9/26 (34.6%) 13/37 (35.1%)  
 High (d11q, d17p, complex karyotype) 0/11
(0%)
3/16 (19%)   4/26 (15.4%) 3/37 (8.1%)  
IgHV UM:M 0:7 0:10 NS 3:14 3:21 NS
CD38 (> 30%) 1/12
(8%)
4/15 (27%) NS 7/28 (25%) 6/45 (13.3%) NS
Lymphocytosis (Giga/L) 30 ± 4 74 ± 12 0.003 57.2 ± 9.2 34.6 ± 3.5 0.05
PFS (median-months)a > 150 44 0.001 46 120 0.0007
TFS (median-months)a > 150 63 0.003 116 > 120 0.02
LDT (median months)a 49 22 0.02 24 36 NS
  1. Abbreviations: NS not significant, No number, SEM standard error of the mean, IGHV immunoglobulin heavy-chain variable region, UM unmutated IGHV, M mutated IGHV, PFS Progression free survival, TFS Treatment free survival, d deletion, tri trisomy, LDT Lymphocyte doubling time; aKaplan-Meyer survival analysis